Zura Bio (ZURA) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ZURA Zura Bio

Watchlist

2.280
-0.060-2.56%

Close Dec 20 16:00 ET

2.280
0.0000.00%

Post 16:11 ET

148.87MMarket Cap-3.49P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Leerink Partners Maintains Zura Bio(ZURA.US) With Buy Rating, Maintains Target Price $12
Moomoo News13:31 ET · Ratings
Zura Bio (ZURA) Receives a Buy From Piper Sandler
TipRanksDec 12 06:46 ET · Ratings
Leerink Partners Maintains Zura Bio(ZURA.US) With Buy Rating, Cuts Target Price to $12
Moomoo NewsDec 12 02:33 ET · Ratings
Optimistic Outlook on Zura Bio: Tibulizumab's Potential and Market Opportunity
TipRanksDec 12 02:06 ET
Express News | Cantor Fitzgerald Reiterates Overweight on Zura Bioto Overweight
BenzingaDec 11 11:21 ET
Express News | Zura Bio Ltd : Leerink Partners Cuts Target Price to $12 From $15
ReutersDec 11 08:23 ET

Comments

Jaguar8

Nov 14 15:32

NEWS

$Zura Bio (ZURA.US)$
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Methodman10

Oct 17 14:32

$Zura Bio (ZURA.US)$ big move ahead. daily chart looks great

Trytosaveabit

Jun 14 05:04

Update

$Zura Bio (ZURA.US)$ Zura Bio Ltd: Tibulizumab (Zb-106) Was Well Tolerated and Neutralized Il-17a and Baff in a Phase 1 Study in Patients With Sjogren's Syndrome! Presents data at EULAR 2024

Drosen21

Jun 12 08:09

Hedgies may be confused over at Cantor…

$Zura Bio (ZURA.US)$ One is overweight and another to buy 🤫

Jaguar8

Jun 3 06:31

NEWS

$Zura Bio (ZURA.US)$
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...

Heat List

Overall

No Data